Author： Saxena Uday
Publisher： Informa Healthcare
ISSN： 1472-8222
Source： Expert Opinion on Therapeutic Targets, Vol.14, Iss.12, 2010-12, pp. : 1273-1277
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
Where Do We Go from Here? The Importance of Initial Values
By Mehta M.A.
Neuropsychopharmacology, Vol. 27, Iss. 5, 2002-11 ,pp. :
Contingency Management for Smoking Cessation: Where Do We Go from Here?
Current Drug Abuse Reviews, Vol. 1, Iss. 3, 2008-11 ,pp. :
COX-2 controversy: where are we and where do we go from here?
Inflammopharmacology, Vol. 13, Iss. 4, 2005-09 ,pp. :
Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?
By Lazaro A.
PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. :